T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
AffiliationDepartment of Medical Oncology, School of Cancer, Enabling Sciences and Technology, The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom.
MetadataShow full item record
AbstractMetastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.
CitationT cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. 2009, 15 (21):6503-10 Clin. Cancer Res.
JournalClinical Cancer Research
- Lymphocyte therapy of renal cell carcinoma.
- Authors: Dillman RO
- Issue date: 2005 Dec
- Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
- Authors: Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V
- Issue date: 2000 Jun
- T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
- Authors: Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E
- Issue date: 2010 Apr 15
- Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
- Authors: Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S
- Issue date: 2008 Nov
- Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
- Authors: Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, Ramon J, Schachter J
- Issue date: 2009 Jan